The Best Years in Life
Articles by Natural Health Author Paul Fassa
|Home Article Directory Health News/Information Healthy Recipes TBYIL Radio Podcasts Remedies Beating/Avoiding Cancer Natural Living Anti-Aging/Longevity Pets/Animals Humor Inspiration The TBYIL Complete Supplement & Health Catalog Contact Us|
Two Big Pharma Players Getting Buried by a Law Suit Avalanche
by Paul Fassa
(The Best Years in Life) Imagine a large bloated beast called Big Pharma slipping into a stream and suddenly attacked by thousands of piranha lawyers and plaintiffs, a satisfying image that happens to be occuring now in the legal world. But unfortunately, it's not all of Big Pharma. There are two key players involved though.
Takeda Pharmaceuticals and Eli Lilly are in that piranha filled stream now over their controversial drug Actos, brand name for pioglitazone, which has been a drug prescribed to reduce diabetes type 2 blood sugar. The potential side effects include: bladder cancer, congestive heart failure, edema, eye edema, fluid in the lungs, and spontaneous fractures.
Amazing, all those risks in exchange for lowering blood sugar with a pill instead of diet and exercise.
The jury believed Alan's contention that the drug companies knew of the bladder cancer risks from using Actos but never gave sufficient warning. Terrence had been using Acto from 2006, and his bladder cancer diagnosis was given in 2011.
That was the year when the FDA ordered black box bladder cancer warnings in exchange for allowing Acto back on the market after it was pulled off momentarily due to mounting adverse reaction reports. Acto was banned completely in France and Germany and it's still off the market there.
These two Big Pharma bulls had managed to survive three of the earlier piranha attacks, mostly on technicalities. But they were finally overwhelmed by a jury's decision to pay plaintiffs Terrence and Susan Alan $1.475 million in compensatory damages and a whopping $9 billion in punitive damages. Takeda is assessed with $6 billion of the punitive award and Eli Lilly is responsible for $3 billion.
Most legal experts think the jury's punitive award amount won't hold up. Legal precedence has established a cap of punitive damages to not exceed 10 times the compensatory amount. This jury awarded way over 10 to one with 9 billion punitive over just under 1.5 million compensatory. But this decision is only the beginning.
There are over 3,000 suits filed against Actos with hearings pending throughout the nation. And now it's expected that up to 10,000 individual suits will be eventually filed. This goes without considering a class action suit, although some speculate that an international class action suit my evolve out of the preponderance of individual legal actions being filled against the same defendants for the same reason.
Takeda Caught Trying to Pull a Fast One; No End in Sight for Takeda or Lily
Gee, what about those studies that led to FDA's initial approval? Maybe some negative study documents didn't make it there, but they were among those that “couldn't be found” or were “missing” after having been requested by the plaintiffs' attorneys prior to jury trial.
These were files that had been compiled by 46 current and former employees involved with the development, marketing, and sales of Actos. One of them was forced into a whistle blower position to report that he and the other 45 employees had been ordered to permanently remove the documents from their internal computer files when the suits started being filed. Two of those employees were directors.
The federal judge, U.S. District Judge Rebecca Doherty, had decided to allow plaintiff attorneys to expose the defendants' “Spoliation of Evidence” to jurors and permit the jury to infer the documents were damaging to the companies' defense. Technically, she had sufficient reason to call a default in favor of the plaintiff. But then perhaps the plaintiff's award would have been much less.
In January of 2014, Judge Doherty into the record: “The breadth of Takeda leadership whose files have been lost, deleted or destroyed is, in and of itself, disturbing.” One of plaintiff Alan's attorneys, Paul J. Pennock, “I think that a verdict like this declares just how outrageous the evidence was regarding Lilly’s and Takeda’s behavior.”
Alan's case was picked out of a cluster of around 3,000 Acto cases pending that were amassed in an MDL (multidistrict litigation) arrangement to be heard in the Louisiana federal district court. The purpose of an MDL is to include several pretrial hearings on similar cases simultaneously and avoid further dragging out the hearings to resolve different individual pretrial decisions from several different judges.
The attorneys for the plaintiffs' strategy is to allow one major case to determine the outcome of others in the defendants' mind and perhaps force settlements on the case in the MDL more as a huge blanket award for a class actions suit. But there are a few hundred other suits pending that weren't included in this MDL that may not be wrapped into a class action suit.
Wishfully, this may be the beginning of the end for both companies, Tekeda and Eli Lily, and scarey enough to enforce less lies by Big Pharma for pushing toxic drugs onto the public. Many consider “ambulance chaser” attorneys as unscrupulous money grubbers.
Me, I'm rooting for the piranha lawyers on this one! Go fishies go, rip up those bulky Big Pharma carcasses!
About the author:
Paul Fassa started looking into natural health to overcome his unhealthy lifestyle. Then he developed more interest as he researched his articles for Natural News and Align Life.